Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Platelet inhibition with clopidogrel has become an important weapon against recurrent coronary events in patients with coronary artery disease. However, recent evidence shows that patient response to clopidogrel is variable, with some patients having suboptimal inhibition of platelet aggregation.

Should We RELOAD Patients on Long-term Clopidogrel?